Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy

Archives of General Psychiatry

Volumn 54, Issue 10, 1997, Pages 959-965

  Bartha, Robert ^a,d   Williamson, Peter C ^b   Drost, Dick J ^b   Malla, Ashok ^b   Carr, Tom J ^b   Cortese, Len ^c   Canaran, Gita ^a   Rylett, R Jane ^a   Neufdd, Richard W J ^b  

^a St Joseph's Health Centre

^b Department of Psychiatry ^*

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMINE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BRAIN LEVEL; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PREFRONTAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

EID: 0031466522     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830220085012     Document Type: Article

References (63)

1. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alternations with deficit syndrome. Arch Gen Psychiatry. 1992:49:522-529.
2. 99mTe exametazime in unmedicated schizophrenic patients. Biol Psychiatry. 1993;33:487-495.
3. Kawasaki Y, Maeda Y, Suzuki M, Urata K, Higaskima M, Kiba K, Yamaguchi N, Matsuda H, Hisada K. SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schwphr Res. 1993:10:109-116.
4. Siegel BV, Buchsbaum MS, Bunney WE, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG, Wu JC. Cortical-striatalthalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry. 1993:150:1325-1336.
5. Ebmeier KP, Lawrie SM, Blackwood DHR, Johnstone EC, Goodwin GM. Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia. J fJeurol Neurosurg Psychiatry. 1995:58:452-456.
6. Dolan RJ, Reicher P, Frith CD, Fristen KJ, Frackowiak RSJ, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 1995:378:180-194.
7. Liddle PF, Fristen KJ, Frith CD, Hirsch SR, Jones T, Frackowiak SJ. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 1992:160:179-186.
8. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G, O'Leary DS. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry. 1992:49:943-958.
9. Gur RE, Mozley D, Resnick SM, Harper Mozley L, Shtasl DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M, Gur RC. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry. 1995:52:657-667.
10. Frith CD, Friston KJ, Herold S, Silbersweig D, Fletcher P, Cahill C, Dolan RJ, Frackowiak RSJ, Liddle PF. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. BrJPsychiatry. 1995:167:343-349.
11. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 1995:378:176-179.
12. Benes FM, Sorensen I, Vincent SL, Bird ED. Increased density of glutamate-immunoreactive vertical process in superficial laminae in cingulate cortex of schizophrenic brain. Cerebral Cortex. 1992:2:503-512.
13. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry. 1991;48:996-1001.
14. 3H] kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett. 1983:40:245-250.
15. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995:52:829-836.
16. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. JNeurochem. 1989:52:1781-1786.
17. Vogt BA. Structural organization of cingulate cortex: areas, neurons, and somatodendritic transmitter receptors. In: Vogt BA, Gabriel M, eds. Neurobiology of Cingulate Cortex and Limbic Thalamus. Boston, Mass: Birkhauser; 1993:19-70.
18. 1H MR spectra. Magn Reson Med. 1995:34: 17-24.
19. Provencher SW. Estimation of metabolite concentrations from localized in-vivo proton NMR spectra. Magn Reson Med. 1994:30:672-679.
20. Michaelis T, Merboldt K, Brunn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology. 1993:187:219-227.
21. Ernst T, Ross BD, Flores R. Cerebral MRS in infants with suspected Reye's syndrome. Lancet. 1992:340:486.
22. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Neuroradiology. 1992:182:19-27.
23. Stanley JA, Wiliiamson PC, Drost DJ, Rylett J, Carr T, Maila A, Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenic patients. Schizophr Bull. 1996:22:597-609.
24. Spitzer R, Williams J. StructuredClinical Interview forDSM-lll-R. New York, NY: New York Psychiatric Institute; 1985.
25. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1994.
26. Andreasen N. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa; 1994.
27. Bryden P. Measuring handedness with questionnaires. Neuropsychologia. 1977; 15:617-624.
28. Liu Z, Javaid T, Hu J, Brown TR. CSI-autoshim procedures for body and surface coil. In: Proceedings of the Society of Magnetic Resonance 2nd Annual Meeting; August 6-12,1994; San Francisco, Calif; Page 1174. Abstract.
29. Tailairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme Medical Publishers Inc; 1988.
30. Frahm J, Merboldt KD, Hanicke W. Localized proton spectroscopy using stimulated echoes. JMagn Reson. 1987;72:502-508.
31. Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hanicke W. Improvements in localized proton NMR spectroscopy of human brain: water suppression, short echo times, and 1 ml resolution. JMagn Reson. 1990:90:464-473.
32. 1H MR spectra. In: Proceedings of the 3rd Society of Magnetic Resonance Meeting; August 19-25,1995; Nice, France. Page 1946. Abstract.
33. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med. 1990;14:26-30.
34. De Beer R, van Ormondt D. Analysis of data using time domain fitting procedures. NMR Basic Principles Prog. 1992:26:201-248.
35. Van den Boogaart A, Ala-Korpela M, Jokisaari J, Griffiths JR. Time and frequency domain analysis of NMR data compared: an application to 1D 'H spectra of lipoproteins. Magn Reson Med. 1994:31:347-358.
36. Marquardt DW. An algorithm for least-squares estimations of non-linear parameters. JSoclndustApplMath. 1963:11:431-441.
37. 1H NMR spectra of human brain. Magn Reson Med. 1994;32:294-302.
38. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson 0. 1994:10:191-247.
39. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imag. 1993;11:107-118.
40. SPSS for Windows: Release 6.0. Chicago, 111: SPSS Inc; 1993.
41. Cochran WG. Analysis of covariance: its nature and uses. Biometrics. 1957;13: 261-281.
42. Lees MC, Neufeld RWJ. Matching the limits of clinical inference to the limits of quantitative methods: a formal appeal to practice what we persistently preach. Can Psychol. 1994:35:268-282.
43. Larzelere RE, Mulaik SA. Single sample tests for many comparisons. Psychol Bull. 1977;4:557-569.
44. Bradford HF, Ward HK, Thomas AJ. Glutamine: a major substrate for nerve endings. JNeurochem. 1978:30:1453-1459.
45. Erecinska M, Silver IA. Metabolism and role of glutamate in mammalian brain. Prog Neurobiol. 1990:35:245-296.
46. 1H spectroscopy: glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 1991:4:59-63.
47. Hamberger AC, Chiang GH, Nylen ES, Schelf SW, Cotman CW. Glutamate as a CNS transmitter, I: evaluation of glucose and glutamine as precursors for the synthesis of preferentially released glutamate. Brain Res. 1979:168:513-530.
48. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. JfJeuroscl. 1993:13:981 -989.
49. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry. 1995:53:805-818.
50. Olney JW, Farber NB. Glutamate receptor dysfunction in schizophrenia. Arch Gen Psychiatry. 1995:52:998-1007.
51. Javitt DC, Zukin SR. Recent advances in the pnencyclidine model of schizophrenia. Am J Psychiatry. 1991:148:1301-1308.
52. Nasrallah PM. In vivo proton magnetic resonance spectroscopy of the hippocampal amygdala region in schizophrenics. Schizophr Res. 1992:6:150.
53. Renshaw PF, Yurgelum-Todd DA, Tohen M, Gruber S, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 1995:152:444-446.
54. Alexander GE, De Long MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9: 357-381.
55. Alexander EA, Crutcher MD, De Long MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog Brain Res. 1990;85:119-146.
56. Rajakumar N, Williamson P, Stoessl J, Flumerfelt B. Neurodevelopmental pathogenesis of schizophrenia. In: Proceedings of the Society of Neuroscience Meeting: 1996; Washington, DC. Vol 2, p 1187.
57. Lipska BK, Jaskiw GE, Chrapasta S, Karoum F, Weinberger DR. Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens in prefrontal cortex. Brain Res. 1992:585(1-2): 1-6.
58. 1H NMR spectroscopy: N-acetyl-Laspartate, creatine, and choline. fJMR Biomed. 1991:4:47-52.
59. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, Alien M. Alternations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics: a pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991:48:563-568.
60. 1H decoupling. In: Proceedings of the Society of Magnetic Resonance Meeting; April 27-May 3,1996; New York, NY. Page 998. Abstract.
61. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, Thompson RT. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 1995:52:399-406.
62. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatry. 1994:36:792-800.
63. Benes FM. Relationship of cingulate cortex to schizophrenia and other psychiatric disorders. In: Vogt BA, Gabriel M, eds. Neurobiology of Cingulate Cortex and Limbic Thalamus. Boston, Mass: Birkhauser; 1993:581-605.